Table 1 Patient characteristics of the derivation and validation cohorts. The serological status of EBV was determined based on the IgM or IgG levels in patients or donors
Derivation cohort (n = 249) | Validation cohort (n = 217) | P value | |
|---|---|---|---|
Patients age, median (range) | 27 (1–66) | 29 (1–64) | ns |
Donors age, median (range) | 39 (9–65) | 36 (8–66) | ns |
Patients gender, n(%) | ns | ||
Male | 152 (61.04) | 135 (62.21) | |
Female | 97 (38.96) | 82 (37.79) | |
Donors gender, n(%) | ns | ||
Male | 185 (74.30) | 156 (71.89) | |
Female | 64 (25.70) | 61 (28.11) | |
Donors age, n(%) | ns | ||
> 50y | 53(21.3%) | 55(25.3%) | |
≤ 50y | 196(78.7%) | 162(74.7%) | |
ABO blood type, n(%) | ns | ||
Match | 127 (51.00) | 123 (56.68) | |
Minor mismatch | 53 (21.29) | 41 (18.89) | |
Major mismatch | 56 (22.49) | 45 (20.74) | |
Mismatch | 13 (5.22) | 8 (3.69) | |
Donor-recipient relationship, n(%) | ns | ||
Patrents to children | 151 (60.64) | 119 (54.84) | |
Children to parents | 56 (22.49) | 56 (25.81) | |
Sibling | 42 (16.87) | 42 (19.35) | |
Donor-recipient gender, n(%) | ns | ||
Male to male | 114 (45.78) | 98 (45.16) | |
Male to female | 71 (28.51) | 59 (27.19) | |
Female to female | 25 (10.04) | 21 (9.68) | |
Female to male | 39 (15.66) | 39 (17.97) | |
Stem cell source, n(%) | < 0.001 | ||
BM + PB | 47 (18.88) | 154 (70.97) | |
PB | 202 (81.12) | 63 (29.03) | |
Serological EBV status of patients and donors, n(%) | ns | ||
P−D− | 1 (0.40) | 1 (0.46) | |
P−D + | 8 (3.21) | 16 (7.37) | |
P + D− | 9 (3.61) | 8 (3.69) | |
P + D + | 231 (92.77) | 192 (88.48) | |
HLA mismatch, n(%) | ns | ||
1 | 15 (6.02) | 14 (6.45) | |
2 | 29 (11.65) | 33 (15.21) | |
3 | 205 (82.33) | 170 (78.34) | |
aGVHD, n(%) | ns | ||
aGVHD- | 150 (60.24) | 101 (46.54) | |
aGVHD grade 1–2 | 84 (33.74) | 101 (46.54) | |
aGVHD grade 3–4 | 15 (6.02) | 15 (6.91) | |
Count of grafts components/kg, median(range) | |||
MNC (108/kg) | 9.39 (6.30–20.25) | 9.70 (5.48–22.45) | ns |
CD34 (106/kg) | 3.95 (1.10–17.64) | 2.78 (0.23–12.69) | < 0.001 |
Lym (106/kg) | 374.98 (91.28–960.46) | 337.62(109.24–1057.09) | < 0.001 |
CD14 (106/kg) | 156.72 (55.11–348.05) | 148.52 (51.71–305.82) | 0.015 |
CD3 (106/kg) | 269.28 (64.62–650.48) | 248.46 (61.95–645.75) | 0.003 |
CD4 (106/kg) | 147.90 (38.39–414.48) | 128.62 (35.68–358.13) | < 0.001 |
CD8 (106/kg) | 91.89 (21.00–277.85) | 93.00 (20.64–297.16) | ns |
NK (106/kg) | 37.47 (6.09–183.20) | 29.12 (3.15–192.20) | 0.005 |
EBV infection, n(%) | 48 (19.28) | 47 (21.66) | ns |
Median time of EBV infection, days (range) | 46 (25–212) | 47 (28–215) | ns |